In Nov. 2022, Chengdu Chipscreen Pharmaceutical Ltd. was certified as a national high-tech enterprise for the first time.
In Aug. 2022, Chipscreen Biosciences' innovative new drug Chiglitazar was rewarded with the Annual New Drug Innovation Award (Domestic) of the "14th Healthy China Forum" issued by People's Daily Health Client and People's Daily Health Times.
In Nov. 2021, Dr. Lu Xianping, Chairman of Chipscreen Biosciences, was awarded the “2021 CABS K. Fong Award in Life Sciences” by the Chinese American Biopharmaceutical Society (CABS).
In Oct. 2021, Chidamide, as a significant technological achievement in the field of medicine, was invited to participate in the national "13th Five-Year Plan" scientific and technological innovation achievement exhibition co-sponsored by the Ministry of Science and Technology, the National Development and Reform Commission, the Ministry of Finance, the Equipment Development Department of the Central Military Commission of the P.R.C., the Science and Technology Commission under the Central Military Commission of the P.R.C., and the Beijing Municipal People's Government, and appeared on Network News Broadcast of CCTV.
In May 2021, Chidamide, as a significant technological achievement in the field of medicine, was selected for the "Centennial Review: The Communist Party of China Leading the Development of Science and Technology" exhibition hosted by the Ministry of Science and Technology of the P.R.C. during the 2021 National Science and Technology Week.
In October 2020, Chipscreen Biosciences was honored as an Outstanding Growth Enterprise of China’s Pharmaceutical Industry and an Outstanding Product Brand by the China Pharmaceutical Industry Association.
In December 2017, Chidamide received a gold award in the 19th Chinese Patent Awards jointly issued by the China National Intellectual Property Administration and the World Intellectual Property Organization.
In March 2017, Chidamide was recognized as the Chinese pharmaceutical brand with the most clinically valuable innovative drugs in 2016 by the Chinese Academy of Medical Sciences, People’s Daily Online and China Pharmaceutical Innovation and Research Deve
In September 2015, Dr. Lu Xianping, Chairman of Chipscreen Biosciences, was awarded the first Pacific Life Science Achievement Award during the 11th Annual Meeting of the Sino-American Biotechnology and Pharmaceutical Association (SABPA).
In September 2015, Dr. Lu Xianping, Chairman of Chipscreen Biosciences, was selected as one of Forbes magazine’s top 10 2015 Sino-American innovators.
In September 2014, Chipscreen Biosciences won the BayHelix and BioCentury Award for R&D Achievement of the Year 2014.
In November 2008, Chipscreen Biosciences was honored as Most Valuable Partner of Roche R&D Center (China).
In October 2008, Chipscreen Biosciences was included in Deloitte’s 2008 China Fast 50 and China Tech Fast 50 lists.
In August 2002, Chipscreen Biosciences was selected as one of the Top 10 Companies to Watch at the Asia-Pacific Life Sciences and Technology Summit.
